一株新的α-糖苷酶抑制剂生产菌株PW0852的初步研究

Study of a Novel Strain PW0852 Producing α-Glucosidase Inhibitor

从土壤中分离并筛选得到了一株α-糖苷酶抑制剂生产菌PW0852。根据形态特征、培养特征、生理生化特征及16S rRNA序列相似性分析等多相分类方法,初步判定菌株PW0852为淡紫灰链霉菌(Streptomyces lavendulae)。该菌经10L发酵罐水平发酵,发酵液中可积累一定量的α-糖苷酶抑制剂。采用膜过滤技术、离子交换树脂吸附及冷冻干燥等方法,从PW0852发酵液中分离获得混合型α-糖苷酶抑制剂GIB852。GIB852对人类胰腺α-淀粉酶和α-麦芽糖酶都有明显的抑制作用,其对麦芽糖酶的抑制性比同剂量的市售双糖酶抑制剂米格列醇强28.7倍,而对α-淀粉酶的抑制性较弱。通过小鼠糖耐量实验,发现α-糖苷酶抑制剂GIB852对哺乳动物餐后高血糖的形成有明显改善作用,具有开发为糖尿病药物的潜力。

Actinomycete strain PW0852 with high production of α-glucosidase inhibitor was isolated from soil samples.Based on the results of morphological,physiological,chemotaxonomic characteristics and 16S rRNA analysis,strain PW0852 was placed within the genus Streptomyces and identified as the species Streptomyces lavendulae.After fermentation in a 10 L fermentor,α-glucosidase inhibitors were accumulated in the harvested broth of strain PW0852.The mixed-type α-glucosidase inhibitor GIB852 we obtained was isolated and purified after ultra-filtration,nano-filtration,resin-adsorption and desiccation.GIB852 could efficaciously inhibit human pancreatic α-amylase and α-maltase glucoamylase.The inhibition of maltase is stronger than the same dose of the commercial α-glucosidase inhibitor miglitol 28.7 times,while the inhibition of α-amylase is weak.GIB852 could significantly depress blood glucose levels in mammalian systems and be developed towards a possible therapeutic agent for diabetes.